Jean Jacques Bienaime Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jean Jacques Bienaime is Director of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 473,792 shares of BMRN, which is worth approximately $28.3 Million. The most recent transaction as insider was on Jun 21, 2021, when has been sold 1,000 shares (Common Stock) at a price of $37.46 per share, resulting in proceeds of $37,460. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K

0% 3M change

0.25% 12M change

Total Value Held $28.3 Million

JEAN JACQUES BIENAIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 21 2021	BUY Exercise of conversion of derivative security	$37,460 $37.46 p/Share	1,000 Added 0.33%	304,839 Common Stock
May 10 2021	SELL Open market or private sale	$657,970 $77.29 p/Share	8,513 Reduced 2.73%	303,839 Common Stock
May 10 2021	BUY Exercise of conversion of derivative security	$225,509 $26.49 p/Share	8,513 Added 2.65%	312,352 Common Stock
May 07 2021	SELL Open market or private sale	$1,964,750 $78.59 p/Share	25,000 Reduced 7.6%	303,839 Common Stock
May 07 2021	BUY Exercise of conversion of derivative security	$662,250 $26.49 p/Share	25,000 Added 7.07%	328,839 Common Stock
May 06 2021	SELL Open market or private sale	$1,958,750 $78.35 p/Share	25,000 Reduced 7.6%	303,839 Common Stock
May 06 2021	BUY Exercise of conversion of derivative security	$662,250 $26.49 p/Share	25,000 Added 7.07%	328,839 Common Stock
Apr 30 2021	BUY Grant, award, or other acquisition	$21,282 $62.41 p/Share	341 Added 0.11%	303,839 Common Stock
Apr 30 2021	BUY Exercise of conversion of derivative security	$37,460 $37.46 p/Share	1,000 Added 0.33%	303,498 Common Stock
Apr 23 2021	SELL Open market or private sale	$793,400 $79.34 p/Share	10,000 Reduced 3.2%	302,498 Common Stock
Apr 23 2021	BUY Exercise of conversion of derivative security	$264,900 $26.49 p/Share	10,000 Added 3.1%	312,498 Common Stock
Apr 22 2021	SELL Open market or private sale	$789,100 $78.91 p/Share	10,000 Reduced 3.2%	302,498 Common Stock
Apr 22 2021	BUY Exercise of conversion of derivative security	$264,900 $26.49 p/Share	10,000 Added 3.1%	312,498 Common Stock
Mar 22 2021	SELL Payment of exercise price or tax liability	$433,352 $78.52 p/Share	5,519 Reduced 1.79%	302,498 Common Stock
Mar 16 2021	SELL Payment of exercise price or tax liability	$429,210 $77.21 p/Share	5,559 Reduced 1.77%	308,017 Common Stock
Mar 15 2021	SELL Payment of exercise price or tax liability	$1,836,364 $78.39 p/Share	23,426 Reduced 6.95%	313,576 Common Stock
Mar 15 2021	BUY Grant, award, or other acquisition	-	41,350 Added 10.93%	337,002 Common Stock
Mar 12 2021	SELL Open market or private sale	$539,700 $77.1 p/Share	7,000 Reduced 2.31%	295,652 Common Stock
Mar 12 2021	BUY Exercise of conversion of derivative security	$185,430 $26.49 p/Share	7,000 Added 2.26%	302,652 Common Stock
Mar 11 2021	SELL Open market or private sale	$543,760 $77.68 p/Share	7,000 Reduced 2.31%	295,652 Common Stock
Mar 11 2021	BUY Exercise of conversion of derivative security	$185,430 $26.49 p/Share	7,000 Added 2.26%	302,652 Common Stock
Mar 04 2021	BUY Small Acquisition	$7,794 $77.94 p/Share	100 Added 0.03%	295,652 Common Stock
Feb 19 2021	SELL Open market or private sale	$585,060 $83.58 p/Share	7,000 Reduced 2.31%	295,552 Common Stock
Feb 19 2021	BUY Exercise of conversion of derivative security	$185,430 $26.49 p/Share	7,000 Added 2.26%	302,552 Common Stock
Feb 18 2021	SELL Open market or private sale	$595,560 $85.08 p/Share	7,000 Reduced 2.31%	295,552 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

IMNM

Immunome Inc. Healthcare

KROS

Keros Therapeutics, Inc. Healthcare

JJB